Mast cells trigger
IgE-mediated
allergic reactions by releasing various allergic mediators. 8-Formyl-7-hydroxy-4-methylcoumarin, also called 4μ8C, was originally known as an
inositol-requiring
enzyme 1 (IRE1) suppressant, but no study has examined its relationship with mast cells and allergic diseases. Therefore, the purpose of this study was to determine whether 4μ8C is effective in suppressing
allergic reactions in mast cells and in
IgE-mediated allergic animal model. 4μ8C suppressed the degranulation of
IgE-mediated mast cells (IC50=3.2μM) and the production of
cytokines such as
tumor necrosis factor-α (TNF-α) and
interleukin-4 (IL-4) in a dose-dependent manner. 4μ8C also suppressed passive cutaneous anaphylaxis (PCA) in mice (ED50=25.1mg/kg). In an experiment on mast cell signaling pathways stimulated by
antigen, the phosphorylation and activation of Syk was decreased by 4μ8C, and phosphorylation of downstream signaling molecules, such as linker for activated T cells (LAT), Akt, and the three MAP
kinases, ERK, p38, and JNK, were suppressed. Mechanistic studies showed that 4μ8C inhibited the activity of Lyn and Fyn in vitro. Based on the results of those experiments, the suppressor mechanism of
allergic reaction by 4μ8C involved reduced activity of Lyn and Fyn, which is pivotal in an
IgE-mediated signaling pathway. In summary, for the first time, this study shows that 4μ8C inhibits Lyn and Fyn, thus suppressing
allergic reaction by reducing the degranulation and the production of inflammatory
cytokines. This suggests that 4μ8C can be used as a new medicinal candidate to control allergic diseases such as seasonal
allergies and
atopic dermatitis.